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Abstract
Background: Long-term management of Parkinson’s disease does not reach its full potential because we lack knowledge about
individual variations in clinical presentation and disease progression. Continuous and longitudinal assessments in real-life (ie,
within the patients’ own home environment) might fill this knowledge gap.
Objective: The primary aim of the Parkinson@Home study is to evaluate the feasibility and compliance of using multiple
wearable sensors to collect clinically relevant data. Our second aim is to address the usability of these data for answering clinical
research questions. Finally, we aim to build a database for future validation of novel algorithms applied to sensor-derived data
from Parkinson’s patients during daily functioning.
Methods: The Parkinson@Home study is a two-phase observational study involving 1000 Parkinson’s patients and 250
physiotherapists. Disease status is assessed using a short version of the Parkinson's Progression Markers Initiative protocol,
performed by certified physiotherapists. Additionally, participants will wear a set of sensors (smartwatch, smartphone, and fall
detector), and use these together with a customized smartphone app (Fox Insight), 24/7 for 3 months. The sensors embedded
within the smartwatch and fall detector may be used to estimate physical activity, tremor, sleep quality, and falls. Medication
intake and fall incidents will be measured via patients’ self-reports in the smartphone app. Phase one will address the feasibility
of the study protocol. In phase two, mathematicians will distill relevant summary statistics from the raw sensor signals, which
will be compared against the clinical outcomes.
Results: Recruitment of 300 participants for phase one was concluded in March, 2016, and the follow-up period will end in
June, 2016. Phase two will include the remaining participants, and will commence in September, 2016.
Conclusions: The Parkinson@Home study is expected to generate new insights into the feasibility of integrating self-collected
information from wearable sensors into both daily routines and clinical practices for Parkinson’s patients. This study represents
an important step towards building a reliable system that translates and integrates real-life information into clinical decisions,
with the long-term aim of delivering personalized disease management support.
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Introduction
Parkinson’s disease (PD) is a progressive and complex
neurological disorder. Patients can experience a wide range of
motor symptoms and signs, including bradykinesia, tremor,
rigidity, and postural instability. Non-motor symptoms include
executive dysfunctions, memory disturbances, attention
difficulties, and reduced ability to smell [1-3].
The cornerstone of current therapy is based on the replacement
of dopamine, but can also include other drugs that play a role
in the activation of dopamine receptors [4]. Although these
medications initially have good results in disease management,
the effects remain successful for a limited period of time. Most
patients eventually develop motor complications, such as the
wearing-off effect or dyskinesias [5,6]. Some disease symptoms,
such as postural instability and voice/speech impairment, are
insufficiently (or sometimes not at all) responsive to
dopaminergic therapy.
Two major problems hamper the delivery of optimal individual
treatment. First, evaluation of day-to-day variations in a complex
disease such as PD is difficult when relying solely upon periodic
consultations with experts working in a clinical setting [7]. Even
when health professionals use specific and validated instruments,
such as the Movement Disorder Society - Unified Parkinson's
Disease Rating Scale (MDS-UPDRS) [8], the results represent
a subjective and episodic snapshot taken under well-controlled
conditions, which are usually not representative of the patient’s
functioning in daily life. More detailed, objective, and reliable
knowledge about real-life functioning would greatly improve
the quality of individual medical management. Second, virtually
all scientific evidence that is presently available to inform PD
management stems from biased clinical studies with short
follow-up periods in highly selected sub-populations, who were
studied under carefully controlled trial conditions [9,10]. As
such, this evidence does not reflect the clinical presentation,
treatment response, or disease progression in actual daily life.
To overcome these limitations, wearable sensors are emerging
as new tools to continuously and longitudinally obtain
information from patients in real-life. The accuracy of sensor
data for everyday activity recognition (eg, walking, running) in
real-life ranges from 58% to 97% [11]. These sensors, typically
consisting of embedded accelerometers, have been used
successfully to determine PD-related symptoms [12-16].
However, to date these studies have relied upon small sample
sizes (n=5 to 43 participants) and short follow-up periods (3
days to 6 months; see Multimedia Appendix 1).
The primary aim of the Parkinson@Home study is to evaluate
the feasibility and patient compliance of using wearable sensors
to collect data for at least 3 months in a large patient group. A
secondary aim of this study is to address the usability of these
data for answering clinically relevant research questions (eg, to
determine the relationship between sensor-derived measures
and clinical measures). Finally, the study aims to build a
database for future development and testing of novel algorithms
applied to sensor-derived data from PD patients during daily
functioning.
Methods
Study Design
The Parkinson@Home study is an observational study involving
1000 patients (from whom data will be recorded) and 250
physiotherapists (who will assist in performing the clinical
assessments, and who may act as personal coaches during
follow-up). Both patients and therapists will be recruited
throughout the Netherlands. The study consists of two phases.
Phase one aims to assess the feasibility of deploying wearable
sensors in a large PD population (n=300). For this purpose,
patients will use a number of wearable devices (Pebble
smartwatch, Android smartphone, and fall detector) in
combination with a customized app (Fox Insight). Follow-up
will occur after 3 months (13 weeks), starting from the moment
the first data are streamed to the server. In addition to using
wearable devices, participants will attend a one-time
consultation, during which a detailed clinical assessment will
be performed by an experienced physiotherapist or a research
team member. This clinical assessment will take place in week
7, or later during the follow-up period. Phase two, which will
include an additional 700 participants, aims to collect raw sensor
data in order to investigate the usability of these data for
answering clinical research questions. This phase will also be
used to build a database for future validation of novel algorithms
applied to sensor-derived data from PD patients during daily
functioning. Patients involved in phase one can also be included
in phase two if they wish. Data collection for clinical results
and device-based outcomes, as well as the follow-up period,
will be identical to phase one. To ensure the success of the raw
data collection during phase two, devices and raw data collection
strategies used in this phase will be chosen after the evaluation
of data collected during phase one.
The study protocol was successfully piloted prior to full study
implementation to ensure methodological feasibility. In total
20 Dutch PD patients participated in this pilot, using a set of
wearable devices (one smartphone and one smartwatch) and
the Fox Insight app. The patients were asked to use these devices
for 24 hours, seven days a week, and were followed for four
weeks. In total, 58% of patients that were approached agreed
to participate. Some patients were reluctant to manage
technology and to deal with possible technical problems, which
caused them to refrain from participation. All participants
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(except for two) needed at least one support call for device
troubleshooting. Streaming compliance for the sensor data was
88%.
Inclusion and Exclusion Criteria
Patients
The inclusion and exclusion criteria for patients will be kept
purposefully broad, in order to represent the full diversity of
real-life PD experiences. Inclusion criteria specify that patients
must be 30 years of age or older, and be diagnosed with PD by
a physician. No exclusion criteria will be applied.
Physiotherapists
Physiotherapists who are members of the Dutch ParkinsonNet
[17,18] are eligible to participate. ParkinsonNet physiotherapists
have received several PD-specific educational training programs,
and treat a high number of PD patients each year.
Physiotherapists who want to participate should take the official
MDS-UPDRS course (provided online by MDS [19], and further
in person training provided by the research team) and be able
to include and/or assess an average of four PD patients for the
study.
Patient Recruitment Process
We will apply an incremental recruitment strategy. Initially, we
will only include patients that already possess a compatible
Android/iPhone smartphone. Subsequently, and only if needed,
we will include patients that do not possess a smartphone; these
patients will be provided with a loaned smartphone device. The
reason for this incremental approach is that patients with their
own device will likely require less technical support from the
research team, as was the case in our pilot study. This strategy
will increase the feasibility of complete data collection in a total
of 1000 patients.
Patients will be recruited both in the community and through
their treating physiotherapists. To reach potential participants
in the community, we will use a number of communication
channels: (1) the ParkinsonConnect community, an online
community for Parkinson’s patients and healthcare professionals
involved in their care [18]; (2) the webpage of the Dutch
Parkinson Patient Association; (3) an article in the magazine of
the Dutch Parkinson Patient Association; (4) presentations about
the study to local patient support groups (Parkinson Cafés); (5)
promotional material for patients will be sent to all ParkinsonNet
physiotherapists (approximately 990 individuals), regardless of
whether they participate in the study or not, and we will ask
them to recruit patients within their practice; and (6) via a study
website [20] which provides information about the study. The
study website offers both patients and physiotherapists the
possibility to sign up for the study online.
After signing up for the study, potential participants will be
contacted by phone by a member of the research team, who will
provide additional information about the study and check
eligibility. If respondents are eligible and willing to participate,
they will receive an informed consent form. After the informed
consent form has been signed digitally, the research team will
provide the participant with all necessary devices and user
manuals.
Recruitment and Training of Physiotherapists
All ParkinsonNet physiotherapists will be contacted by email
to inquire about study participation. Should this email not result
in adequate numbers of participating physiotherapists, we will
personally contact ParkinsonNet physiotherapists by telephone.
As with the recruitment process for patients, after signing up
via the study website, physiotherapists will be contacted by
email or phone to check eligibility.
Once included, physiotherapists must pass the online
MDS-UPDRS training successfully [19], as required by the
International Parkinson and Movement Disorder Society, which
allows them to perform the MDS-UPDRS [8]. After successful
completion of the training, physiotherapists will participate in
one face-to-face training session, in which they will assess one
patient, in order to practice the MDS-UPDRS assessment and
consolidate their understanding of the assessment process and
study procedures.
Ethical Aspects and Trial Registration
This study will be conducted in compliance with the Ethical
Principles for Medical Research Involving Human Subjects, as
defined in the Declaration of Helsinki. The study protocol and
communication materials have been approved by the local ethics
committee (Commissie Mensgebonden Onderzoek,
Arnhem-Nijmegen; NL53034.091.15).
Consent will be obtained by the research team through an
innovative online procedure, which includes a compulsory
cooling-off period in a digital environment. When the patient
is deemed eligible (eg, meets the inclusion criteria specified in
the online sign-up form), an information letter and consent form
will be send by email. The research team and an independent
physician can be approached for questions and verbal
explanation. Next, the potential participant has the possibility
to confirm participation digitally, via a new URL sent to him/her
by email after 48 hours. The URL redirects the patient to the
study webpage, where he/she can confirm that they have read
all information and that they agree to participate. As
recommended by the ethics committee, this final step is blocked
for 48 hours after the first email has been sent, to ensure that
potential participants take time to consider participation. After
the agreement to participate, the participant will see a
confirmation message on the study webpage. No signature or
scanning of documents will be necessary at this point. The
Parkinson@Home study is registered in the ClinicalTrials.gov
registry (NCT02474329) [21].
Wearable Sensors Phase One
Pebble Smartwatch
The Pebble is a commercially available smartwatch, with a
variety of embedded sensors, such as tri-axial accelerometer,
light sensor, and magnetometer. Accelerometers are able to
record acceleration along three orthogonal spatial axes,
producing acceleration vectors as single data points, and up to
100 acceleration data vectors can be recorded per second. The
Pebble smartwatch operating software allows access to the
unprocessed raw accelerometer data vectors, creating the
opportunity for subsequent analyses of this sensor data. In order
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to obtain continuous accelerometer data, the Fox Insight app
will be installed on each smartwatch. The app enables streaming
of the accelerometer data to the smartphone, with a sampling
frequency of 50 data vectors per second, using the built-in
Bluetooth radios of both the smartwatch and smartphone.
Fox Insight App
The Fox Insight app is an Android/iPhone app created and
developed by Intel Corporation (Tel Aviv, Israel). This app
receives 50 accelerometer data points per second from the
Pebble smartwatch, and estimates levels of activity, tremor, and
sleep movement analyses using dedicated algorithms running
within the app. The app presents these estimated quantities to
the user by means of graphs and summary reports of the data
collected.
Activity graphs show the level of activity throughout the day
(Figure 1). The calculation is performed by aggregations (30
second intervals) of the raw data previously collected. The graph
also highlights the moments in time when medication was taken.
Daily tremor graphs show how many minutes the patient has
experienced tremor during a certain day (a tremor is defined as
any movement in the range of 3.5-12Hz). Sleep analysis graphs
(Figure 2) show the amount of time that the patient has been
active during the sleep time. These graphs provide an impression
of the intensity and duration of movements.
These estimated quantities are sent every 10 minutes to a
cloud-based data platform through an Internet connection on
the smartphone. Different mechanisms allow the participants
to know whether the data are recorded correctly. First,
participants can check the metric graphs (eg, activity graph,
sleep analysis, and tremor); these graphs are plotted using the
data recorded in the servers, and will only appear if the data
were collected. Second, the main app screen (Figure 3) displays
how many hours of data the participant has contributed to the
study; if this metric does not increase it means the data are not
being collected. Finally, participants can view the white pill
icon in the smartphone task bar; if the icon has a crossing line
over it, data are not being actively recorded.
Figure 1. Fox Insight Mobile App activity graph.
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Figure 2. Fox Insight Mobile App sleep analysis graph.
Figure 3. Fox Insight Mobile app main screen.
Fall Detector
Falls and movement patterns are measured with a pendant
device. Patients are given the choice to wear either a fall detector
(FD), or the Philips Mobility Monitor (PMM) [22,23]. Both
sensors are CE-marked non-medical devices; the PMM is
developed by Philips Research. The FD device used in this study
is an adapted fall detection device, originally intended for seniors
living in their own homes, that was designed to detect falls from
stance. The FD device can be worn 24/7, while the PMM is
recharged overnight and thus only worn during the day.
The FD device uses multiple sensors and a proprietary analytical
algorithm to detect some types of fall events, which are stored
in the device. The PMM contains a 3-axial accelerometer and
a barometric pressure sensor, with a sampling frequency of
50Hz and 25Hz, respectively. Data are continuously recorded
and stored on a micro SD card within the device. Based on these
data, information about the daily movements, as well as falls
detected, are calculated after read-out at the end of each patient’s
trial period.
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Wearable Sensors Phase Two
Devices will be chosen after analysis of the study procedure,
and data collection is complete in phase one.
Technical Support
Patients will have access to extended support, including an
installation guide, user manual, and information on the study’s
webpage. For the duration of the study, a helpline will be
available during working hours to support the installation and
device usage, and for troubleshooting.
Clinical and Feasibility Assessment
Certified physiotherapists will perform the short version of the
Parkinson Progression Marker Initiative (PPMI) in order to
assess disease status [24]. This assessment includes: the
MDS-UPDRS (parts I, III, and IV) for disease rating [8]; the
Montreal Cognitive Assessment for cognition [25]; and the
Modified Schwab and England Activities of Daily Living Scale
for activities of daily living [26].
Additional questionnaires will be completed by the patients:
MDS-UPDRS part II for motor experiences of daily living; the
Scales for Outcomes in Parkinson’s Disease - Autonomic System
(SCOPA-AUT) for autonomic dysfunction [27]; the Geriatric
Depression Scale for depressive symptoms [28]; and the
Epworth Sleepiness Scale for day sleepiness [29].
To assess feasibility, patients will also complete the System
Usability Scale [30] and a satisfaction survey created by the
research team, to address patients’ impressions on how well
particular features of the app are functioning, and the burden
associated with the methodology. An overview of outcomes is
provided in Multimedia Appendix 2.
Data Collection and Management
Due to privacy issues, patients will receive a personal
identification code that does not contain any information that
relates to the individual. The key-file, connecting personal
identification codes to personal information, will be stored on
a Radboudumc data server, and only the research team has
access to the key-file. The key-file will be stored on a different
server from the study data for five years, allowing the research
team to contact patients after they have finished the study. We
anticipate that our efforts to obtain additional research funding
will allow for additional follow-up assessments. The key-file
will be destroyed after five years.
Data for the study will be collected in the following ways:
Data from smartwatch and smartphone: data will be collected
continuously in a coded manner, and will be transferred to Intel’s
cloud data storage environment using an Internet connection.
The cloud environment is based on Amazon Web Services, and
developed and managed by Intel’s Advanced Analytics team.
Data from the watch and Fox Insight app will be transferred to
the Intel platform using a personal identification code for each
patient. Moreover, no personally identifiable data will be entered
into the app or sent to this data storage platform.
Data from the PMM and FD: data will be collected during the
time that patients are not lying in bed. Each FD has a unique
identifier, and Philips Research will only receive coded data.
No personal information is required to use these devices, and
no personal data from patients will be shared with Philips.
Data from the clinical assessments: data will be collected by
means of paper-based forms, and will be entered manually into
an online certified data management system. Forms will only
contain personal identification codes.
Data from support and logistics: ZenDesk software will be used
to support the logistics of the recruitment process, and provide
technical support during the follow-up phase. ZenDesk is
Internet-based, and data access is authenticated by username
and password. All communications with ZenDesk servers use
industry-standard Secure Sockets Layer encryption by default,
and the ZenDesk servers are located at a different site than the
Amazon servers. Therefore, research data is never stored on the
same server as patients’ identifying codes.
Patients that complete the clinical assessment and stream data
for more than seven days will have their data included in further
analyses.
Data Analyses
Phase One
Feasibility and compliance will be addressed using descriptive
analyses. For feasibility, the primary outcomes will include the
total support time per participant, the number and rate of
drop-outs, usability of the system, bias within recruitment
strategies, and the type of problems faced by patients. Regarding
compliance, the outcome measures include the total hours of
sensor data collected per participant, the number of compliant
days, and the percentage of time that sensor data were streamed
during the follow-up period.
Phase Two
The potential for the data to answer clinically relevant research
questions will be explored. First, we aim to extract a limited set
of outcomes, including: the number, diversity, and performance
of physical activities; specific activities (eg, standing, walking,
sitting); response fluctuations in relation to drug treatment; and
specific motor symptoms (eg, tremor, gait freezing, shuffling,
falls).
Additionally, we aim to explore how these outcomes are related
to clinical assessments, and to self-monitoring during follow-up
(including timing of medication intake and fall incidents).
Finally, we aim to extract patterns of disease progression, assess
the recognition of disease profiles based on reported symptoms
and progression patterns, and address the effect of medication
intake on symptoms. In both phases, analyses will be performed
using specialized algorithms (when necessary) developed within
the Matlab platform, with additional statistical analyses using
the R software package.
Results
Patient Recruitment Process
Within eight months of recruitment (August, 2015 to March,
2016) the Parkinson@home study received 1164 applications.
Among those invited for phase one (n=342), the participation
rate was 87.7%, resulting in 300 inclusions. Recruitment
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strategies through the network of the Dutch Parkinson
Association, and a personal approach by the research team or
health care providers, have been very successful (Table 1).
Applicants include all respondents that demonstrated interest
in the study, while participants include all respondents that were
actually included in the study (which excludes dropouts and
those who refused to participate). Phase two will begin in
September, 2016, and participants will be recruited from the
734 participants placed in the study waiting list.
Table 1. Number of applications obtained from each recruitment strategy.
Participants n=258
(%)
Applicants n=1164
(%)
Recruitment Strategy
8 (3.10)12 (1.03)Online community for patients (ParkinsonConnect)
20 (7.75)142 (12.19)Website of the Dutch Parkinson Association
100 (38.75)451 (38.74)Article in the magazine of the Dutch Parkinson Association
36 (13.95)112 (9.62)Informative presentation at Parkinson Cafés by research team
31 (12.02)198 (17.04)Personal invitation by Physiotherapist or Neurologist
51 (19.77)224 (19.24)Others
12 (4.65)25 (2.14)Not specified
Discussion
In this paper we present the rationale and design of the
Parkinson@Home study, a large (n=1000) observational cohort
study that aims to explore the feasibility and usability of
collecting raw sensor data from wearable sensors in patients
with PD. There is a pressing need for collection of reliable
medical information from PD patients while they perform
activities of daily living, due to gaps in knowledge as to why
different patients have variable rates of PD progression and
different patterns of symptoms [31,32]. It has proven to be
extremely difficult to understand such variations, and to capture
objective data about the patient’s actual functioning in current
clinical practice, which typically consists of episodic and brief
clinical evaluations in hospitals.
Gathering data from wearable sensors has high scientific
potential and offers several advantages compared to more
traditional methods of data collection. Wearable sensors offer
the possibility to collect data by self-administered tests, and to
objectively monitor PD symptoms and day-to-day variation
both remotely and at home [33-35]. The raw sensor data can be
analyzed later by specialized algorithms or by algorithms
embedded in apps themselves, providing scientific insights for
researchers and clinicians. Moreover, data can be collected
continuously over a prolonged period of time. For individual
PD patients, those data can be used for long-term health
monitoring. When applied in a group context, the data may offer
a better understanding of PD (eg, by revealing the presence of
specific phenotypic subtypes, or by predicting disease
progression) [36].
Using wearable sensors also brings about challenges. First, data
from sensors are a potential target for invasions of privacy [37].
For example, Global Positioning System-based sensor data can
be used to identify the physical location of an individual, and
their homes [38]. As a remedy, approaches such as restricting
access to the data and anonymizing files have been suggested
[39]. To allow for the collection of sensitive data, and to address
security issues, the Parkinson@Home project will adopt several
precautions, including: coding the data; storing the data on
secure servers, separately from personal data; and restricting
data use, by only allowing access to authorized researchers
within the research team. When making information available
to the wider research community, data will be anonymized and
access will be granted only through a secure research database.
These actions decrease the risk of identification of the patient
and inappropriate use of the data.
A second challenge faced in the Parkinson@Home study is the
lack of experience that elderly people have with technical
devices. This lack of experience affects the acceptance of, and
compliance with, the technology [40]. Overcoming this lack of
experience in our target population, without introducing a
selection bias, will be a challenge. However, we believe that
the best approach for this issue is to rely on the willingness of
patients to learn and be engaged in the management of their
disease, combined with an efficient support model.
In conclusion, this study will generate new insights into the use
of wearable sensors in daily living by PD patients, and if the
data collection shows potential, it will make a contribution to
the integration of self-collected information into clinical practice
for PD patients. This study represents the first steps towards
building a reliable system that integrates real-life information
into clinical decisions.
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